---
trial_id: 483
discovery_date: 2022-04-05 21:16:14.461185
date: 2022-04-05 21:16:14.461185
title: "A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re..."
summary: |
  <p>EudraCT Number: 2019-004822-15<br />Sponsor Protocol Number: GNC-401<br />Sponsor Name: GeNeuro Innovation SAS<br />Start Date: 2020-05-18<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004822-15/SE">SE</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004822-15'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2019-004822-15<br />Sponsor Protocol Number: GNC-401<br />Sponsor Name: GeNeuro Innovation SAS<br />Start Date: 2020-05-18<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004822-15/SE">SE</a> (Completed)</p>